This conference has been withdrawn from the 2020 conference schedule
As you are aware, coronavirus is having a global impact and the World Health Organization and the Centers for Disease Control have instituted recommendations that include social distancing and cancelling conferences and large gatherings. Since safety of our attendees is always GRC's highest priority, the GRC Board of Trustees has decided to withdraw this conference and it will be rescheduled for 2022. This decision was made out of an abundance of caution and to alleviate the concerns of our conference communities that are scheduled to meet in this timeframe.
Proteoglycans are biologically active components of the extracellular matrix consisting of a specific protein core post-translationally modified and covalently linked with linear glycosaminoglycans consisting of repeating disaccharides. The diversity in composition resulting from the various combinations of protein cores substituted with one or more glycosaminoglycan chains enables proteoglycans to interact with a host of different cell surface receptors, cytokines, growth factors, proteases, and other extracellular components. An emerging body of evidence indicates that secreted proteoglycans act as signaling molecules in addition to their canonical function in maintaining and regulating the architecture of various extracellular matrices. These interactions result in modulation of pivotal cellular processes e.g. differentiation, proliferation, growth, adhesion, migration, autophagy, angiogenesis, and survival under developmental, physiological and pathological conditions. Therefore, proteoglycans are crucial regulators of cancer development, angiogenesis, fibrosis, inflammation, immunity, regenerative medicine, and diseases of the musculoskeletal and neuronal systems, and lung, renal and cardiovascular diseases.
The program of the 2020 Proteoglycans GRC entitled "Frontiers in Basic and Translational Proteoglycan Research to Improve Human Health" will highlight the latest findings in fundamental proteoglycan research addressing biosynthesis and catabolism as well as advances in the technologies used to study proteoglycans and glycosaminoglycans. A major focus of the 2020 Proteoglycans GRC is to underscore proteoglycans as therapeutic tools and targets. Thus, recent advances from preclinical studies using animal models to clinical studies targeting proteoglycans for treatment of various human diseases will lead to discussions among basic scientists and clinical researchers from academia, research institutes, and the pharmaceutical industry.